BioAge Labs, Inc.
BIOANASDAQHealthcare● Active
$15.51
$-0.19(-1.21%)
Market Cap$583945839
P/E Ratio—
52W High$24
52W Low$4.065
BioAge Labs, Inc. (BIOA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BIOA · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.52
Est. -$0.64 · +18.7%
Revenue
$0.00B
Est. $0.00B · +155.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 3-Quarter EPS Beat Streak
BIOA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.06
Rev. $1.94B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.06
Rev. Est.$1.94B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$0.65 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.64 | -$0.52 | +18.7% | $0.00B | $0.00B | +155.9% |
| ▲ Q1 FY2026 | Mar 24, 2026 | -$0.83 | -$0.72 | +13.3% | $0.00B | $0.00B | +119.9% |
| ▲ Q4 FY2025 | Nov 6, 2025 | -$0.67 | -$0.56 | +16.4% | $0.00B | $0.00B | +80.2% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -$0.56 | -$0.60 | -7.1% | $0.00B | $0.00B | +177.2% |
| ▲ Q2 FY2025 | May 6, 2025 | -$0.52 | -$0.36 | +30.8% | $0.00B | $0.00B | +150.2% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -$0.58 | -$1.97 | -239.7% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.72 | -$6.70 | -830.6% | — | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$0.65
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.52
EPS Est.
-$0.64
EPS Surpr.
+18.7%
Revenue
$0.00B
Q1 FY2026
Mar 24, 2026Beat
EPS Actual
-$0.72
EPS Est.
-$0.83
EPS Surpr.
+13.3%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
-$0.56
EPS Est.
-$0.67
EPS Surpr.
+16.4%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Miss
EPS Actual
-$0.60
EPS Est.
-$0.56
EPS Surpr.
-7.1%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$0.36
EPS Est.
-$0.52
EPS Surpr.
+30.8%
Revenue
$0.00B
Q1 FY2025
Mar 20, 2025Miss
EPS Actual
-$1.97
EPS Est.
-$0.58
EPS Surpr.
-239.7%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$6.70
EPS Est.
-$0.72
EPS Surpr.
-830.6%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $-0.89 | $-0.62 | $-0.35 | 2 |
| Q3 FY2028 | $-0.79 | $-0.55 | $-0.31 | 2 |
| Q2 FY2028 | $-0.82 | $-0.57 | $-0.33 | 2 |
| Q1 FY2028 | $-0.82 | $-0.57 | $-0.32 | 2 |
| Q4 FY2027 | $-0.90 | $-0.62 | $-0.35 | 1 |
| Q3 FY2027 | $-0.83 | $-0.58 | $-0.33 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +18.7% | $17.82 | $17.99 | +0.95% |
| ▲ Q1 FY2026 | Mar 24, 2026 | +13.3% | $18.63 | $16.11 | -13.53% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +16.4% | $7.50 | $7.47 | -0.40% |
| ▼ Q3 FY2025 | Aug 6, 2025 | -7.1% | $4.44 | $4.33 | -2.48% |
| ▲ Q2 FY2025 | May 6, 2025 | +30.8% | $4.15 | $3.95 | -4.82% |
| ▼ Q1 FY2025 | Mar 20, 2025 | -239.7% | $4.44 | $4.38 | -1.35% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -830.6% | $22.94 | $20.62 | -10.11% |
| — Q3 FY2024 | Sep 26, 2024 | — | No price data | $18.31 | — |
Q2 FY2026+0.95%
Report Date
May 8, 2026
EPS Beat/Miss
+18.7%
Price Before
$17.82
Price After
$17.99
Q1 FY2026-13.53%
Report Date
Mar 24, 2026
EPS Beat/Miss
+13.3%
Price Before
$18.63
Price After
$16.11
Q4 FY2025-0.40%
Report Date
Nov 6, 2025
EPS Beat/Miss
+16.4%
Price Before
$7.50
Price After
$7.47
Q3 FY2025-2.48%
Report Date
Aug 6, 2025
EPS Beat/Miss
-7.1%
Price Before
$4.44
Price After
$4.33
Q2 FY2025-4.82%
Report Date
May 6, 2025
EPS Beat/Miss
+30.8%
Price Before
$4.15
Price After
$3.95
Q1 FY2025-1.35%
Report Date
Mar 20, 2025
EPS Beat/Miss
-239.7%
Price Before
$4.44
Price After
$4.38
Q4 FY2024-10.11%
Report Date
Nov 7, 2024
EPS Beat/Miss
-830.6%
Price Before
$22.94
Price After
$20.62
Q3 FY2024—
Report Date
Sep 26, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$18.31
Avg Beat Reaction-4.45%
Avg Miss Reaction-4.65%
Beat Rate4 / 8 quarters
Largest Move-13.53% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BIOA ends December
BioAge Labs, Inc. (BIOA) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.52 — beating the analyst consensus of $-0.64 by +18.7%. BIOA has beaten EPS estimates for 3 consecutive quarters. The next BIOA earnings date is expected around September 1, 2026.
Each quarter, investors track BIOA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BIOA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BIOA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BIOA earnings · 5 questionsBioAge Labs, Inc.'s next earnings report is expected around September 1, 2026. BIOA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BIOA historically reports after market close (AMC).
BIOA earnings datewhen is BIOA earningsBIOA next earnings datewhen does BIOA report earningsBIOA earnings calendar
▸ Source: FMP · BioAge Labs, Inc. SEC filings · US GAAP · BioAge Labs, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026